Direct Initiation of Levodopa–Carbidopa Intestinal Gel Infusion After a Positive Levodopa Challenge Test in Advanced Parkinson's Disease
Brain and Behavior · 2024
DOI: 10.1002/brb3.70193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2024. Verfasst von Vili Viljaharju und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Carbidopa, Drug Combinations. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helsinki University Hospital, University of Helsinki, Finnish Parkinson Foundation.
Abstract (Originalsprache)
Introduction
Levodopa–carbidopa intestinal gel (LCIG) is an established treatment option in advanced Parkinson's disease (PD). LCIG treatment is usually initiated with a nasojejunal tube (NJT) test phase before percutaneous endoscopic transgastric jejunostomy (PEG‐J) tube installation. However, some centers have used direct initiation with PEG‐J. Data comparing these approaches are scarce. The objective of this study was to analyze the risks and benefits of direct PEG‐J initiation after a positive levodopa challenge test (LCT) for selected patients compared to initiation with a temporary NJT test phase.
Methods
Thirty‐three consecutive advanced PD patients commenced LCIG‐treatment between February 2016 and December 2019 at Helsinki University Hospital. Of them, 11 (33%) selected patients had direct initiation without an NJT test phase. Treatment discontinuations and adverse events during the first 6 months of treatment were evaluated retrospectively. The duration of hospital stay related to the initiation of the treatment was compared between the groups.
Results
Between the direct initiation and NJT test phase groups, there were no significant differences in treatment discontinuations (0 vs. 1, respectively); the number of inner tube or PEG‐J tube replacements (1 vs. 3); or infection complications (1 vs. 3) during the first 6 months of treatment. Direct initiation significantly reduced the hospital stay related to treatment initiation (mean 7 vs. 9 days, p = 0.001).
Conclusion
For selected patients, the direct initiation of LCIG after a positive LCT, without a temporary NJT test phase, appears safe and does not lead to additional treatment discontinuations or complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
- Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland.
- Department of Gastroenterological Surgery, Helsinki University Hospital, Helsinki, Finland.
ORCID-Profile: Vili Viljaharju, Maija Koivu, Marianne Udd
Förderung
- Helsinki University Hospital
- University of Helsinki
- Finnish Parkinson Foundation
- Helsingin Yliopisto
Zitieren
APA
Viljaharju, V., Mertsalmi, T., Pauls, K. A. M., Koivu, M., Eerola-Rautio, J., Udd, M., & Pekkonen, E. (2024). Direct Initiation of Levodopa–Carbidopa Intestinal Gel Infusion After a Positive Levodopa Challenge Test in Advanced Parkinson's Disease. Brain and Behavior. https://doi.org/10.1002/brb3.70193
Vancouver
Viljaharju V, Mertsalmi T, Pauls KAM, Koivu M, Eerola-Rautio J, Udd M, et al. Direct Initiation of Levodopa–Carbidopa Intestinal Gel Infusion After a Positive Levodopa Challenge Test in Advanced Parkinson's Disease. Brain and Behavior. 2024. doi:10.1002/brb3.70193
BibTeX
@article{Viljaharju2024,
author = {Viljaharju, Vili and Mertsalmi, Tuomas and Pauls, K Amande M and Koivu, Maija and Eerola-Rautio, Johanna and Udd, Marianne and Pekkonen, Eero},
title = {Direct Initiation of Levodopa–Carbidopa Intestinal Gel Infusion After a Positive Levodopa Challenge Test in Advanced Parkinson's Disease},
journal = {Brain and Behavior},
year = {2024},
doi = {10.1002/brb3.70193}
}
EUVIMED